Federal Grant Award Summary

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Johns Hopkins University a Project Grant of $169,927 beginning April 1, 2026 through March 31, 2031 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This award supports research evaluating the comparative effectiveness of glucose-lowering therapies in people with HIV (PWH) and type 2 diabetes during the era of modern antiretroviral therapy (ART). The research addresses a critical knowledge gap regarding optimal pharmacologic management of diabetes in this population, which experiences unique metabolic challenges including chronic inflammation and disrupted glucose and lipid metabolism.

Under this award, the principal investigator—an internal medicine physician with pharmacoepidemiology expertise—will generate real-world evidence on the comparative effectiveness of five commonly used glucose-lowering agents: metformin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, and sulfonylureas. The project encompasses three primary aims: characterizing utilization patterns of glucose-lowering therapies in PWH; evaluating comparative effectiveness on glycemic control; and estimating effects on cardiovascular, renal, and mortality outcomes. The investigator will receive mentorship from a multidisciplinary team with expertise in diabetes, cardiometabolic comorbidities in PWH, machine learning, and causal inference methods, supporting his long-term career development as an independent clinician-investigator.